Ann Rehabil Med.  2013 Jun;37(3):420-425. 10.5535/arm.2013.37.3.420.

A Case of the Cauda Equina Syndrome Associated With the Intrathecal Chemotherapy in a Patient With Primary Central Nervous System Lymphoma

• Park S
• Kang JI
• Bang H
• Kim BR
• Lee J

• KMID: 2219540
• DOI: http://doi.org/10.5535/arm.2013.37.3.420

Abstract

The intrathecal chemotherapy with methotrexate and cytarabine arabinoside is used for the treatment and prophylaxis of the primary central nervous system lymphoma. The therapy may induce neurotoxicity including the cauda equina syndrome. We report a case of a 58-year-old man with the diffuse large B-cell lymphoma, who developed the cauda equina syndrome after the administration of intrathecal methotrexate and cytarabine arabinoside, as diagnosed by the electrodiagnostic, urodynamic, and radiologic approaches.

Keyword

Cauda equina syndrome; Chemotherapy; Intrathecal injections

MeSH Terms

Cauda Equina
Central Nervous System
Cytarabine
Humans
Injections, Spinal
Lymphoma
Lymphoma, B-Cell
Methotrexate
Polyradiculopathy
Urodynamics
Cytarabine
Methotrexate

Figure

• 

  Fig. 1 Spinal computed tomography of the patient. (A) Sagittal image and (B) axial image at the L4-5 intervertebral disc level. L4, 4th lumbar vertebra; L5, 5th lumbar vertebra.

Reference

1. Lee CH, Oh MK, Cho JH, Lee ES, Shin HS. A case of paraplegia associated with intrathecal methotrexate: a case report. J Korean Acad Rehabil Med. 2006; 30:188–190.

2. Kwong YL, Yeung DY, Chan JC. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol. 2009; 88:193–201. PMID: 19050889.

3. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007; 109:3214–3218. PMID: 17209054.

4. Kim JI, Roh JK, Myung H, Kim JM. A case of paraplegia following intrathecal methotrexate instillation. J Korean Neurol Assoc. 1990; 8:145–150.

5. Lee HY, Im SI, Kang MH, Kim KM, Kim SH, Kim HG, et al. Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia. Yonsei Med J. 2008; 49:151–154. PMID: 18306482.

6. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973; 289:770–773. PMID: 4517004.

7. Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E 3rd. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975; 45:189–195. PMID: 1091308.

8. Park SY, Park HR, Kim JE, Sung JJ. Intrathecal chemotherapy related myelopathy improved with folate and cyanocobalamin. J Korean Neurol Assoc. 2011; 29:224–226.

9. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol. 1983; 1:546–551. PMID: 6583325.

10. Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol. 2012; 25:119–130. PMID: 22409828.